Adaptimmune Therapeutics ADAPY
OTC ADAPY
$0.03 0.00 (-13.33%)
As of: Oct 21, 2026 · 12:27 PM EDT

Adaptimmune Therapeutics PLC (ADAPY) Operating Income (2015 - 2025)

Updated

Adaptimmune Therapeutics (ADAPY) posted Operating Income of -$30.29 million for Q2 2025, compared with $68.7 million a year earlier.

Analysis

Adaptimmune Therapeutics PLC (ADAPY) Operating Income (2015 - 2025) Analysis & Trends

For the trailing twelve months through Jun 30, 2025, Operating Income at Adaptimmune Therapeutics was -$164.22 million; for FY2024, it came in at -$68.76 million.

  • In prior years, Adaptimmune Therapeutics' Operating Income was -$139.74 million in FY2023, -$163.97 million in FY2022, -$162.25 million in FY2021 and -$133.41 million in FY2020.
  • Quarterly Operating Income has run from a low of -$73.52 million in Q4 2024 to a high of $68.7 million in Q2 2024 over five years.
  • According to Business Quant data, Operating Income for the three prior quarters was -$45.73 million (Q1 2025), -$73.52 million (Q4 2024) and -$14.68 million (Q3 2024).
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -30.29 Mn
Mar 31, 2025 -45.73 Mn
Dec 31, 2024 -73.52 Mn
Sep 30, 2024 -14.68 Mn
Jun 30, 2024 68.70 Mn
Mar 31, 2024 -49.26 Mn
Dec 31, 2023 -49.86 Mn
Sep 30, 2023 -46.63 Mn
Jun 30, 2023 -44.91 Mn
Mar 31, 2023 1.66 Mn
Dec 31, 2022 -27.24 Mn
Sep 30, 2022 -42.99 Mn
Jun 30, 2022 -43.75 Mn
Mar 31, 2022 -49.98 Mn
Dec 31, 2021 -42.86 Mn
Sep 30, 2021 -42.18 Mn
Jun 30, 2021 -39.31 Mn
Mar 31, 2021 -37.89 Mn
Dec 31, 2020 -37.51 Mn
Sep 30, 2020 -35.88 Mn
API Access

Adaptimmune Therapeutics PLC Operating Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-income&ticker=ADAPY&period=max&api_key=YOUR_API_KEY